Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Randomised Phase II/III Study of Rituximab and Ibrutinib (RI) Versus Dexamethasone, Rituximab and Cyclophosphamide (DRC) as Initial Therapy for Waldenstrom's Macroglobulinaemia

Next Previous
Trial Profile

Randomised Phase II/III Study of Rituximab and Ibrutinib (RI) Versus Dexamethasone, Rituximab and Cyclophosphamide (DRC) as Initial Therapy for Waldenstrom's Macroglobulinaemia

Status: Recruiting
Phase of Trial: Phase II/III

Latest Information Update: 14 May 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Ibrutinib (Primary) ; Rituximab (Primary) ; Cyclophosphamide; Dexamethasone
  • Indications Waldenstrom's macroglobulinaemia
  • Focus Therapeutic Use
  • Acronyms RAINBOW

Most Recent Events

  • 09 May 2024 Planned End Date changed from 28 Feb 2029 to 1 Mar 2030.
  • 09 May 2024 Planned primary completion date changed from 28 Aug 2024 to 1 Mar 2030.
  • 09 May 2023 Planned primary completion date changed from 28 Feb 2029 to 28 Aug 2024.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top